✦ LIBER ✦

The novel complement inhibitor CMSD1 protein promotes Factor I-mediated degradation of C4b and C3b and inhibits MAC assembly and C9 polymerisation

✍ Scribed by Escudero-Esparza, A.; Kalchishkova, N.; Kurbasic, E.; Jiang, W.G.; Blom, A.M.

Book ID: 123315540
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 58 KB
Volume: 56
Category: Article
ISSN: 0161-5890
DOI: 10.1016/j.molimm.2013.05.080

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The novel complement inhibitor human CUB

The novel complement inhibitor human CUB and Sushi multiple domains 1 (CSMD1) protein promotes factor I-mediated degradation of C4b and C3b and inhibits the membrane attack complex assembly

✍ Escudero-Esparza, A.; Kalchishkova, N.; Kurbasic, E.; Jiang, W. G.; Blom, A. M. 📂 Article 📅 2013 🏛 The Federation of American Societies for Experimen 🌐 English ⚖ 462 KB

Cloning and characterization of the prom

Cloning and characterization of the promoter for the human complement factor I (C3b/C4b inactivator) gene

✍ J.O. Minta; May Fung; Stephen Turner; R. Eren; L. Zemach; M. Rits; Gabriel Goldb 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 241 KB

Regulatory proteins for the activated th

Regulatory proteins for the activated third and fourth components of complement (C3b and C4b) in mice. I. Isolation and characterization of factor H: the serum cofactor for the C3b/C4b inactivator (Factor I)

✍ Taroh Kinoshita; Victor Nussenzweig 📂 Article 📅 1984 🏛 Elsevier Science 🌐 English ⚖ 684 KB

The Functional Inhibition of C{ie} Inhib

The Functional Inhibition of C{ie} Inhibitor in Normal Human Serum Causes Spontaneous Consumption of the Complement Components C2, C3, C4, and Factor B

✍ Gronski, P.; Bodenbender, L.; Kanzy, E.-J.; Piepenbrock, M.; Seiler, F.R. 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 615 KB

Correction to Discovery of a Novel Class

Correction to Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazin-6-yl)-1 H -pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer

✍ Cui, J. Jean; McTigue, Michele; Nambu, Mitchell; Tran-Dubé, Michelle; Pairish, M 📂 Article 📅 2012 🏛 American Chemical Society 🌐 English ⚖ 124 KB